Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tongjitang Chinese Medicines Acquired by Winteam for $393 Million

publication date: May 27, 2013
Tongjitang Chinese Medicines will be bought by Winteam Pharmaceutical Group at a price of $393 million. Both companies focus on TCM drugs for markets in mainland China. The price represents a substantial profit for Xiaochun Wang, Tongjitang’s President and CEO, who, along with Fosun Pharma, took the company private two years ago at a price of $138 million. Earlier this year, Sinopharm, China’s largest pharma enterprise, bought a 57% stake in Winteam for $252 million. More details....

Stock Symbols: (HK: 570) (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital